Table 2. Prior treatment (ITT population).
| High risk | Standard risk | Unknown/missing | ||||
|---|---|---|---|---|---|---|
| Kd (n=97) | Vd (n=113) | Kd (n=284) | Vd (n=291) | Kd (n=83) | Vd (n=61) | |
| Number of prior regimens,a n (%) | ||||||
| 1 | 44 (45.4) | 53 (46.9) | 149 (52.5) | 144 (49.5) | 39 (47.0) | 35 (57.4) |
| 2 | 37 (38.1) | 37 (32.7) | 86 (30.3) | 95 (32.6) | 34 (41.0) | 13 (21.3) |
| 3 | 16 (16.5) | 22 (19.5) | 49 (17.3) | 52 (17.9) | 10 (12.0) | 13 (21.3) |
| Prior therapy, n (%) | ||||||
| Bortezomib | 54 (55.7) | 61 (54.0) | 150 (52.8) | 158 (54.3) | 46 (55.4) | 33 (54.1) |
| Carfilzomib | 0 | 0 | 1 (0.4) | 0 | 1 (1.2) | 1 (1.6) |
| Lenalidomide | 43 (44.3) | 51 (45.1) | 100 (35.2) | 104 (35.7) | 34 (41.0) | 22 (36.1) |
| Thalidomide | 47 (48.5) | 62 (54.9) | 126 (44.4) | 152 (52.2) | 38 (45.8) | 33 (54.1) |
Abbreviations: ITT, intention-to-treat; Kd, carfilzomib and dexamethasone; Vd, bortezomib and dexamethasone.
a
One patient in the bortezomib group (high risk) had four prior regimens.